Novo Nordisk’s blockbuster weight-loss drug Wegovy has been approved for sale in China, opening the door to a huge market in which obesity rates have more than doubled among adults in the past two decades.
The Danish pharmaceutical company said on Tuesday that Wegovy “has been approved in China for long-term weight management” for overweight and obese people. It did not say when the product would launch and declined to share details on pricing or the volume of Wegovy it would supply to the region.
Shares in Copenhagen-listed Novo Nordisk were up 2.1 per cent following the announcement, which was initially shared on the company’s account on Chinese social media platform WeChat.
您已阅读32%（683字），剩余68%（1472字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。